Ido Weinberg, MD

From the current issue: Primary results of the SAVAL randomized trial. buff.ly/3tHlVUo #CLTI #PeripheralArteryDisease #VascularTwitter

Online First! @GiacomoBuso and colleagues share humbling data suggesting high rates of symptomatic vascular events in patients with vascular Ehlers-Danlos syndrome despite celiprolol therapy. #VEDS #VEDSAwarenss

@drpete222 @MGHVascular @GParmar_MD @DougDrachmanMD @MGHHeartHealth Peter, thank you :) If you "comment" on the video, I can "reply" and that way other viewers will have this insight.

@Angiologist @MGHVascular @GParmar_MD @DougDrachmanMD @MGHHeartHealth Or for LIMA use during CABG…

Subclavian artery stenosis - Most patients are asymptomatic. Medical therapy is key. Procedures are for symptoms. Learn more here: youtu.be/LIqsK6DSmns @MGHVascular @GParmar_MD @DougDrachmanMD @MGHHeartHealth

Did you know there is ~25% added #mortality in patients with #PAD compared to those who don’t? Join the discussion w/ @GParmar_MD @MGHVascular to learn more about PAD & mortality benefits of low #LDL youtu.be/iv_2yIhki0o?si… @PVDCouncil @lipiddoc @nationallipid @lipid @hmpVDM

Avoid this MISTAKE in BLOOD PRESSURE measurement*,** youtu.be/mf4OsX4Nr6A?si… *Ok. I hate clickbait too. Measure BP in BOTH arms. But still, watch the short clip, LIKE, SHARE, SUBSCRIBE. **Yup. That's my BP, HR and hair... @EricSecemskyMD @GParmar_MD @VladLakhter @SVM_tweets

It’s not just “go home & walk” Home based walking exercise does work if done right. Coaching & connecting with patients is also crucial. It was incredible to have Dr McDermott & @CardioNeela , the lead authors of the article, join the discussion! @AlexVakiliMD @emoryheart #SVM

@bbikdeli @PERTConsortium @GParmar_MD @AndrewDicksMD @SVM_tweets Excellent point. I wonder how various trial data will look if we could see the breakdown of criteria for int-high risk category eligibility.

@Angiologist @PERTConsortium @GParmar_MD @AndrewDicksMD @SVM_tweets 🙏🙏 Thx so much! If confirmed for other hs-cTn assays, IMHO, we should revisit the current situation. Am concerned that some pts may be overtreated w “int-high” risk PE designation off of hs-cTn.

I often don't know what to do with high-sensitivity troponin. Congratulations @bbikdeli et al. for helping confirm our suspicion that we should take it with a grain of salt... jamanetwork.com/journals/jamac… @PERTConsortium @GParmar_MD @AndrewDicksMD maybe a @SVM_tweets JC paper? ;)

Are you interested in #Cardiology #VascularSurgery #VascularMedicine #IR ? Don’t miss this amazing learning opportunity for #residents #fellows #APPs ! Registration is now OPEN! Join #SVM & register today veritasamc.us16.list-manage.com/track/click?u=… @heatherlgornik @adityasharmamd @RKolluriMD

In case you missed it! #GivingTuesday is Today! Join the movement and support #SVM by donating to this amazing cause -> members.vascularmed.org/i4a/ams/public… youtube.com/shorts/cabD-87… @EstherSHKimMD @adityasharmamd @GBarnesMD @RKolluriMD @Angiologist @herbaronowMD @stanhenkin

@mmonrealriete Thank you for including me on this paper!

Patients with brain cancer have a much higher risk for intracranial bleeding during anticoagulation for VTE Find it here: rpthjournal.org/action/showPdf…

"How do I manage anticoagulation around my procedure?" is one of the more common questions we get asked. So I put together this short explainer: youtu.be/2aBC9ZZP1OU?si… @mmonrealriete @adityasharmamd @GParmar_MD @stanhenkin @VladLakhter @AnticoagForum

20 years ago, cancer patients with VTE had similar rates of 30-day recurrence or major bleeding during anticoagulation Nowadays, major bleeds are 2-fold more common than VTE recurrences Safety is the issue

EKOS vs Flowtriever thrombectomy is not always a straightforward decision. Risk of bleeding 🩸 is REAL for both groups although no difference in 30-day readmission, in-hospital death, or ischemic strokes. mcusercontent.com/a8631a3042d8dd… #VascMedJC #SVM @VMJ_SVM @VladLakhter

Among 244 VTE patients with severe renal failure receiving enoxaparin for 6 months, VTE recurrences were less common than major bleeding: 4.1 vs. 13% But during the first 10 days, fatal PE was 5-fold more common than fatal bleeding: 2.1 vs. 0.4% Here: pubmed.ncbi.nlm.nih.gov/37832588/

Did you know the story behind @EricIsselb96027 ’s license plate?😂 #Aorta #SVM youtu.be/WjS0nXm9KUM?si… @MGHHeartHealth @GBarnesMD @YogenKanthi @stanhenkin @adityasharmamd @AorticDissectUS @AorticTrauma @AorticDissectUK @AHAScience @ThinkAorta @AorticDissectCT

@2Scottish @UR_Med @hopkinsheart Love the socks!

Great to connect with my past mentor Charlie Lowenstein (Postdoc Mentor 20 years ago, past ⁦@UR_Med⁩ Chair for eight years), now ⁦@hopkinsheart⁩ Chair. Welcome to #Cleveland !

Peripheral artery disease (PAD), common and serious, doesn't receive enough attention. Many people suffer leg symptoms with walking, but never receive appropriate care. I made this video to help #patients understand what to do: youtu.be/9-f5SESI7a4?si… @GParmar_MD @MGHVascular